日报更新时间：
周报更新时间：04-11 03:39
今开价：139.68
最高价：139.8
成交量：368682.0
昨收价：137.99
最低价：136.52
最新价：137.01
英文名称：Shockwave Medical, Inc .
简介：ShockWave Medical, Inc.成立于2009年6月17日,是一家专注于开发和商业化产品的医疗器械公司，旨在改变钙化心血管疾病的治疗方式
电话：1-510-2794262
ShockWave Medical公司的目标是通过其用于治疗钙化斑块的声压力波的差异化和专有的局部输送（公司将其称为血管内碎石术——intravascular lithotripsy，IVL），建立医疗器械治疗动脉粥样硬化性心血管疾病的新的护理标准。ShockWave Medical公司的IVL系统（IVL System）利用其IVL技术（IVL Technology）——一种微创、易于使用且安全的方法——可显着改善患者的治疗效果。ShockWave Medical的Shockwave M5 IVL导管（M5导管）于2018年4月获得欧盟CE认证，并于2018年7月被美国食品和药物管理局（FDA）批准用于IVL系统，用于治疗外周动脉疾病（PAD）。ShockWave Medical目前在欧洲销售的Shockwave C2 IVL导管（C2导管）于2018年6月通过CE认证，用于治疗冠状动脉疾病（CAD）的IVL System。此外，公司还正在开展多项产品和适应症的临床计划，如果成功，将使公司能够将其产品的商业化扩展到更多的地区以及更多的适应症上。重要的是，ShockWave Medical还正在进行C2导管的持续临床试验，旨在支持美国的上市前申请（PMA），以及Shonin在日本提交的CAD治疗方案。公司预计，这些正在进行的临床试验的最终数据将支持其C2导管产品2021年上半年在美国推出，并将于2021年下半年在日本上市。
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| J.P. Morgan Investment Management, Inc. | 190156 | 0.68% | -16867 | -8.15% | 2019-07-31 |
| RA Capital Management, LLC | 495608 | 1.77% | 495608 | -- | 2019-03-31 |
| Sectoral Asset Management Inc | 849811 | 3.03% | 849811 | -- | 2019-03-31 |
| VHCP Management II, LLC | 901256 | 3.22% | 901256 | -- | 2019-03-31 |
| Gilder Gagnon Howe & CO LLC | 1332559 | 4.76% | 1332559 | -- | 2019-03-31 |
| Fidelity Management & Research Company | 1441809 | 5.15% | 43896 | 3.14% | 2019-07-31 |
| T. Rowe Price Associates, Inc. | 1894776 | 6.76% | 1894776 | -- | 2019-03-31 |
| Fidelity Management and Research Company | 3664711 | 13.08% | 3664711 | -- | 2019-03-31 |
| FMR Inc | 3712811 | 13.25% | 3712811 | -- | 2019-03-31 |
| Fidelity Management Trust Co | 328275 | 1.17% | -- | -- | 2019-07-31 |
| Deerfield Management Co | 312146 | 1.11% | 312146 | -- | 2019-03-31 |
| Redmile Group, LLC | 300000 | 1.07% | 300000 | -- | 2019-03-31 |
| Adage Capital Partners Gp LLC | 200000 | 0.71% | 200000 | -- | 2019-03-31 |
| Morgan Stanley Investment Management, Inc. | 208987 | 0.75% | 208987 | -- | 2019-03-31 |
| BlackRock Fund Advisors | 221824 | 0.79% | 11221 | 5.33% | 2019-07-31 |
| Morgan Stanley - Brokerage Accounts | 232080 | 0.83% | 232080 | -- | 2019-03-31 |
| Lord, Abbett & Co LLC | 237571 | 0.85% | 237571 | -- | 2019-03-31 |
| Citadel Advisors Llc | 257617 | 0.92% | 257617 | -- | 2019-03-31 |
| Capital World Investors | 300000 | 1.07% | 300000 | -- | 2019-03-31 |
| Vanguard Investments Australia Ltd | 192695 | 0.69% | 117900 | 157.63% | 2019-07-31 |
| Capital Research and Management Company | 300000 | 1.07% | 300000 | -- | 2019-06-30 |
| Perceptive Advisors LLC | 150000 | 0.54% | 150000 | -- | 2019-03-31 |
| PGIM Investments LLC | 102692 | 0.37% | -- | -- | 2019-05-31 |
| Millennium Management LLC | 72368 | 0.26% | 72368 | -- | 2019-03-31 |
| Wellington Management Company LLP | 74305 | 0.27% | 74305 | -- | 2019-03-31 |
| Wells Fargo Funds Management LLC | 78757 | 0.28% | 11588 | 17.25% | 2019-05-31 |
| The Variable Annuity Life Insurance Company | 94086 | 0.34% | 94086 | -- | 2019-05-31 |
| Bellevue Group AG | 100000 | 0.36% | 100000 | -- | 2019-03-31 |
| Goldman Sachs Group Inc | 126064 | 0.45% | 126064 | -- | 2019-03-31 |
| Alyeska Investment Group, L.P. | 70212 | 0.25% | 70212 | -- | 2019-03-31 |
| AH Lisanti Capital Growth LLC | 58110 | 0.21% | 58110 | -- | 2019-03-31 |
| Fidelity SelectCo, LLC | 77000 | 0.28% | 77000 | -- | 2019-04-30 |
| Vanguard Group Inc | 49857 | 0.19% | 49857 | -- | 2019-04-30 |
| T. Rowe Price | 49700 | 0.18% | 49700 | -- | 2019-04-30 |
| Columbia Mgmt Investment Advisers, LLC | 44029 | 0.16% | 44029 | -- | 2019-04-30 |
| DWS Investment Management Americas, Inc. | 18242 | 0.07% | 18242 | -- | 2019-04-30 |
| JPMorgan Chase Bank | 16028 | 0.06% | 16028 | -- | 2019-04-30 |
| K2/D&S Management Co., L.L.C. | 10134 | 0.04% | 10134 | -- | 2019-04-30 |
| Deutsche Asset Management Investment GmbH | 10001 | 0.04% | 10001 | -- | 2019-04-30 |
| SEB Investment Management AB | 10000 | 0.04% | 10000 | -- | 2019-04-30 |
| Hartford Funds Management Company, LLC | 9100 | 0.03% | 9100 | -- | 2019-04-30 |
| Lisanti Capital Growth, LLC | 8650 | 0.03% | 8650 | -- | 2019-04-30 |
| JP Morgan Asset Management (UK) Ltd | 8000 | 0.03% | 8000 | -- | 2019-04-30 |
| Vanguard | 143 | -- | 143 | -- | 2019-04-30 |
| Advantus Capital Management. | 971 | -- | 971 | -- | 2019-04-30 |
| MML Investment Advisers, LLC | 1770 | 0.01% | 1770 | -- | 2019-04-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| iShares Russell 2000 Growth ETF | 61865 | 0.22% | 1915 | 3.19% | 2019-07-30 |
| JPMorgan Small Cap Growth Fund | 160874 | 0.57% | -15291 | -8.68% | 2019-06-30 |
| iShares Russell 2000 ETF | 153985 | 0.55% | 9303 | 6.43% | 2019-07-30 |
| American Funds SMALLCAP World Fund | 150000 | 0.54% | -150000 | -50.00% | 2019-06-30 |
| Lord Abbett High Yield Fund | 125197 | 0.45% | -57666 | -31.54% | 2019-05-31 |
| Fidelity | 104000 | 0.37% | -2200 | -2.07% | 2019-06-30 |
| PGIM Jennison Health Sciences Fund | 102692 | 0.37% | -- | -- | 2019-06-30 |
| Vanguard Small Cap Growth Index Fund | 102587 | 0.37% | 102587 | -- | 2019-06-30 |
| T. Rowe Price Small-Cap Stock Fund | 90560 | 0.32% | -1700 | -1.84% | 2019-06-30 |
| Vanguard Extended Market Index Fund | 82290 | 0.29% | 72989 | 784.74% | 2019-06-30 |
| T. Rowe Price New Horizons Trust | 77545 | 0.28% | 47286 | 156.27% | 2019-06-30 |
| T. Rowe Price Health Sciences Port | 66216 | 0.24% | -1 | -- | 2019-06-30 |
| Vanguard Small Cap Index | 177718 | 0.63% | 108122 | 155.36% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 192695 | 0.69% | 117900 | 157.63% | 2019-06-30 |
| Fidelity Growth Company Commingled Pool | 297475 | 1.06% | -- | -- | 2019-06-30 |
| T. Rowe Price New Horizons Fund | 322282 | 1.15% | 79123 | 32.54% | 2019-06-30 |
| T. Rowe Price Health Sciences Fund | 1199065 | 4.28% | -3 | -- | 2019-06-30 |
| Wells Fargo Emerging Growth Fund | 56575 | 0.20% | 67 | 0.12% | 2019-05-31 |
| Morgan Stanley Inst Inception Port | 52085 | 0.19% | 52085 | -- | 2019-03-31 |
| T. Rowe Price Instl Small-Cap Stock Fund | 46412 | 0.17% | 46412 | -- | 2019-03-31 |
| EQ/Morgan Stanley Small Cap Growth Port | 40347 | 0.14% | -- | -- | 2019-04-30 |
| Fidelity Blue Chip Growth Cmmngld Pool | 30800 | 0.11% | 8837 | 40.24% | 2019-04-30 |
| SEB Nordamerikafond Sm | 38943 | 0.14% | 28943 | 289.43% | 2019-04-30 |
| VALIC Company I Health Sciences Fund | 77274 | 0.28% | 77274 | -- | 2019-03-31 |
| Multi-Manager Small Cap Equity Strat Fd | 29929 | 0.11% | 29929 | -- | 2019-03-31 |
| DWS Health and Wellness Fund | 18242 | 0.07% | 18242 | -- | 2019-03-31 |
| Securian T. Rowe Price Sm Cap Stock SP 1 | 971 | -- | 971 | -- | 2019-03-31 |
| Keith D. Dawkins | Currently, Keith D. Dawkins holds the position of Chairman of InnovHeart Srl and Chief Medical Officer of Shockwave Medical, Inc. Dr. Dawkins is also on the board of Avicena LLC and JenaValve Technology, Inc. Dr. Dawkins previously held the position of Global Chief Medical Officer & Executive VP at Boston Scientific Corp. and President at British Cardiovascular Society. Keith D. Dawkins received an undergraduate degree from the University of London. |
|---|---|
| Frederic H. Moll | Dr. Frederic H. Moll, MD, is Independent Director at BIOLASE, Inc., Independent Director at Intersect ENT, Inc., Chairman at Restoration Robotics, Inc., Senior Advisor at Kearny Venture Partners, Chairman & Chief Executive Officer at Auris Surgical Robotics, Inc., and Chairman at ShockWave Medical, Inc. He is on the Board of Directors at Reflexion Medical, Inc., BIOLASE, Inc., Intersect ENT, Inc., and Tibion Corp. Dr. Moll was previously employed as Independent Director by MAKO Surgical Corp., Co-Founder by INSPIRATION Medical GmbH, Vice President & Medical Director by Intuitive Surgical, Inc., Medical Director-Surgical Device Division by Guidant Corp., Co-Founder by Origin Medsystems, Inc., an Advisor by Catalyst Health Ventures, and Founder by EndoTherapeutics. He also served on the board at Hansen Medical, Inc., Aptus Endosystems, Inc., and Innovative Spinal Technologies, Inc. He received his undergraduate degree from the University of California, Berkeley, a graduate degree from Stanford University, and a doctorate degree from UW Medicine. |
| Laura A. Francis | Ms. Laura A. Francis is an Independent Director at Shockwave Medical, Inc. and a COO, Chief Financial & Accounting Officer at SI-BONE, Inc. She is on the Board of Directors at Shockwave Medical, Inc. Ms. Francis was previously employed as a Chief Financial Officer by Auxogyn, Inc., a Chief Financial Officer, Treasurer & VP-Finance by Promega Corp., a Chief Financial Officer by Bruker BioSciences Corp., a Chief Financial Officer by Nutra-Park, Inc., a Chief Financial Officer by Hypercosm LLC, an Engagement Manager by McKinsey & Co., Inc., and an Audit Manager by Coopers & Lybrand LLP. She also served on the board at Stemina Biomarker Discovery, Inc. She received her undergraduate degree from the University of Wisconsin and an MBA from Stanford Graduate School of Business. |
| Jay T. Watkins | Founder of Gynecare, Inc. (New Jersey) and Origin Medsystems, Inc., Jay T. Watkins is a businessperson who has been the head of 5 different companies and holds the position of Chairman for Reflexion Medical, Inc. and Chairman for C2 Therapeutics, Inc. He is also on the board of 7 other companies. In the past Mr. Watkins held the position of Consultant at McKinsey & Co., Inc., Managing Director at De Novo Ventures, Chairman at ReCor Medical, Inc., President for Guidant Compass Group, Principal at Microgenics Corp., President-Minimally Invasive Surgery Group at Guidant Corp. and Director at Gynecare, Inc. (New Jersey). Mr. Watkins received an MBA from Harvard University and an undergraduate degree from Stanford University. |
| Antoine Papiernik | Currently, Antoine Papiernik is Chairman & Managing Partner at Sofinnova Partners SAS. Mr. Papiernik is also on the board of 12 other companies. Mr. Papiernik previously occupied the position of Investment Director at CDC Entreprises Innovation. He received an MBA from The Wharton School of the University of Pennsylvania. |
| Ray Larkin | Ray Larkin is a businessperson who has been the head of 11 different companies. Currently, Mr. Larkin is Chairman of Shockwave Medical, Inc., Chairman for REVA Medical, Inc., Chairman at Align Technology, Inc., Venture Partner at Cutlass Capital LLC, Chairman at Novasys Medical, Inc. and Non-Executive Chairman for HeartWare Pty Ltd. Mr. Larkin is also Chairman at St. Mary's College of California and Principal at Group Outcome LLC and on the board of 5 other companies. In the past Ray Larkin held the position of Member-Executive Committee at Synecor LLC, Manager-National Sales at Bentley Laboratories LLC, Chairman & Chief Executive Officer for Eunoe, Inc., Chairman of HeartWare International, Inc., President & Chief Executive Officer of Nellcor Puritan Bennett, Inc., President & Chief Executive Officer at Nellcor, Inc., Principal at United States Marine Corps and President for Advanced Medical Technology Association. Mr. Larkin received an undergraduate degree from LaSalle University. |
| Douglas Evan Godshall | Presently, Douglas Evan Godshall is President, Chief Executive Officer & Director at Shockwave Medical, Inc. He is also on the board of EyePoint Pharmaceuticals, Inc. and The Medical Device Manufacturers Association. In his past career Mr. Godshall occupied the position of President-Vascular Surgery at Boston Scientific Corp., President, Chief Executive Officer & Director at Heartware Pty Ltd., President & Chief Executive Officer for HeartWare, Inc. and President, CEO, Executive Director & MD at HeartWare International, Inc. He received an undergraduate degree from Lafayette College and an MBA from Northeastern University. |
| John Colin Cahill | Mr. John C. Cahill is Vice President at Venrock Associates. He is on the Board of Directors at Reflexion Medical, Inc., 10X Genomics, Inc. and ShockWave Medical, Inc. Mr. Cahill also served on the board at Simpirica Spine, Inc. Colin previously observed on the boards of Achaogen (AKAO) and Ariosa Diagnostics (acquired by Roche). Mr. Cahill received his undergraduate degree from Stanford University, an M.S. in Biological Sciences at Stanford University and an MBA from Stanford Graduate School of Business. |
| Daniel Puckett | Presently, Daniel Puckett occupies the position of Chief Financial officer & Secretary at Shockwave Medical, Inc. In his past career Mr. Puckett occupied the position of Principal at Viad Corp., Head-Senior Finance & Operations at Affymetrix, Inc., Chief Financial Officer at Ariosa Diagnostics, Inc., Chief Financial Officer at Counsyl, Inc., Principal at Oath, Inc., Principal at BHP Billiton Group Ltd., Principal at Forest Laboratories, Inc. and Executive Director at Cerexa, Inc. Mr. Puckett received an MBA from the University of San Francisco and an undergraduate degree from Washington State University. |
| Hajime Tada | Currently, Hajime Tada occupies the position of General Counsel at Shockwave Medical, Inc. In his past career he occupied the position of Vice President & General Counsel of Agilent Technologies, Inc. He received an undergraduate degree from Yale University and a graduate degree from New York University School of Law. |
| W. Patrick Stephens | Presently, W. Patrick Stephens occupies the position of Vice President-Research & Development for Shockwave Medical, Inc. In his past career he was Vice President-Research & Development for Endologix, Inc. and Vice President-Product Development at Trivascular Technologies, Inc. (a subsidiary of Endologix, Inc.). Mr. Stephens received a graduate degree from the University of Arizona and an undergraduate degree from The University of Colorado. |
| Beaux Alexander | Presently, Beaux Alexander holds the position of Vice President-Clinical Affairs at Shockwave Medical, Inc. Mr. Alexander previously was Senior Director-Clinical Research at Medtronic Vascular, Inc. He received an undergraduate degree from The Ohio State University and an MBA from Georgia State University. |
| Robert Fletcher | Currently, Robert Fletcher occupies the position of Vice President-Marketing at Shockwave Medical, Inc. Mr. Fletcher received an MBA from Kellogg School of Management and an undergraduate degree from the University of Florida. |
| Cathy Harnett | Cathy Harnett is Director-Human Resources at Shockwave Medical, Inc. |
| Mike Maszy | Currently, Mike Maszy occupies the position of Vice President-Operations at Shockwave Medical, Inc. In his past career Mr. Maszy was Vice President-Manufacturing at Endologix, Inc. and Vice President-Manufacturing at TriVascular, Inc. (a subsidiary of Endologix, Inc.). Mr. Maszy received an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree and a graduate degree from the University of Florida. |
| Rob Williamson | Currently, Rob Williamson occupies the position of Vice President-Sales at Shockwave Medical, Inc. In his past career he occupied the position of Sales Director of ZOLL Medical Corp. He received an undergraduate degree from Auburn University. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论